デフォルト表紙
市場調査レポート
商品コード
1009772

重症筋無力症の世界市場:治療別(医薬品、外科、その他)、最終用途別(病院、診療所、その他)、地域別の、市場規模調査と予測(2021年~2027年)

Global Myasthenia Gravis Market Size study, by Treatment (Medication, Surgery and Others), by End Use (Hospitals, Clinics and Others) and Regional Forecasts 2021-2027

出版日: | 発行: Bizwit Research & Consulting LLP | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
重症筋無力症の世界市場:治療別(医薬品、外科、その他)、最終用途別(病院、診療所、その他)、地域別の、市場規模調査と予測(2021年~2027年)
出版日: 2021年06月05日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の重症筋無力症の市場規模は2020年に約10億米ドルとなり、2021年~2027年の予測期間中に7.2%を超える健全な成長率で成長すると予想されています。

重症筋無力症は、骨格筋の衰弱を引き起こす慢性の自己免疫および神経筋疾患です。筋肉が活発になると病気が悪化し、休息すると改善します。これらの影響を受けた筋肉は、腕、脚、および体の他の部分の呼吸と移動に関与しています。

当レポートでは重症筋無力症の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、治療・最終用途・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の定義と範囲

第3章 市場力学

  • 市場の影響分析(2019年~2027年)

第4章 業界分析

  • ポーターのファイブフォースモデル
  • PEST分析
  • 投資採用モデル
  • アナリストの推奨事項と結論

第5章 治療別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2018年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 医薬品
    • 手術
    • その他

第6章 最終用途別

  • 市場のスナップショット
  • パフォーマンス:潜在的な分析
  • 市場規模予測:2018年~2027年(10億米ドル単位)
  • サブセグメント分析
    • 病院
    • クリニック
    • その他

第7章 地域別

  • 地域市場のスナップショット
  • 北米
    • 米国
    • カナダ
  • 欧州のスナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋地域のスナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカのスナップショット
    • ブラジル
    • メキシコ
  • その他の地域

第8章 競合情報

  • トップ市場戦略
  • 企業プロファイル
    • Alexion Pharmaceutical Inc
    • Grifols SA
    • Avadel Pharmaceuticals, Plc.
    • Novartis
    • Pfizer, Inc.
    • AbbVie Inc.
    • F.Hoffmann-La Roche AG
    • GlaxoSmithKline Plc.
    • Bausch Health Companies Inc.
    • Shire plc

第9章 調査プロセス

図表

LIST OF TABLES

  • TABLE 1. Global Myasthenia Gravis Treatment Market, report scope
  • TABLE 2. Global Myasthenia Gravis Treatment Market estimates & forecasts by region 2018-2027 (USD Billion)
  • TABLE 3. Global Myasthenia Gravis Treatment Market estimates & forecasts by Treatment 2018-2027 (USD Billion)
  • TABLE 4. Global Myasthenia Gravis Treatment Market estimates & forecasts by End-Use 2018-2027 (USD Billion)
  • TABLE 5. Global Myasthenia Gravis Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 6. Global Myasthenia Gravis Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 7. Global Myasthenia Gravis Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 8. Global Myasthenia Gravis Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 9. Global Myasthenia Gravis Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 10. Global Myasthenia Gravis Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 11. Global Myasthenia Gravis Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 12. Global Myasthenia Gravis Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 13. Global Myasthenia Gravis Treatment Market by segment, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 14. Global Myasthenia Gravis Treatment Market by region, estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 15. U.S. Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 16. U.S. Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 17. U.S. Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 18. Canada Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 19. Canada Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 20. Canada Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 21. UK Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 22. UK Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 23. UK Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 24. Germany Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 25. Germany Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 26. Germany Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 27. RoE Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 28. RoE Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 29. RoE Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 30. China Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 31. China Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 32. China Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 33. India Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 34. India Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 35. India Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 36. Japan Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 37. Japan Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 38. Japan Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 39. RoAPAC Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 40. RoAPAC Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 41. RoAPAC Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 42. Brazil Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 43. Brazil Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 44. Brazil Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 45. Mexico Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 46. Mexico Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 47. Mexico Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 48. RoLA Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 49. RoLA Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 50. RoLA Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 51. Row Myasthenia Gravis Treatment Market estimates & forecasts, 2018-2027 (USD Billion)
  • TABLE 52. Row Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 53. Row Myasthenia Gravis Treatment Market estimates & forecasts by segment 2018-2027 (USD Billion)
  • TABLE 54. List of secondary sources, used in the study of global Myasthenia Gravis Treatment Market
  • TABLE 55. List of primary sources, used in the study of global Myasthenia Gravis Treatment Market
  • TABLE 56. Years considered for the study
  • TABLE 57. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Myasthenia Gravis Treatment Market, research methodology
  • FIG 2. Global Myasthenia Gravis Treatment Market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Myasthenia Gravis Treatment Market, key trends 2020
  • FIG 5. Global Myasthenia Gravis Treatment Market, growth prospects 2021-2027
  • FIG 6. Global Myasthenia Gravis Treatment Market, porters 5 force model
  • FIG 7. Global Myasthenia Gravis Treatment Market, pest analysis
  • FIG 8. Global Myasthenia Gravis Treatment Market, value chain analysis
  • FIG 9. Global Myasthenia Gravis Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 10. Global Myasthenia Gravis Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 11. Global Myasthenia Gravis Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 12. Global Myasthenia Gravis Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 13. Global Myasthenia Gravis Treatment Market by segment, 2018 & 2027 (USD Billion)
  • FIG 14. Global Myasthenia Gravis Treatment Market, regional snapshot 2018 & 2027
  • FIG 15. North America Myasthenia Gravis Treatment Market 2018 & 2027 (USD Billion)
  • FIG 16. Europe Myasthenia Gravis Treatment Market 2018 & 2027 (USD Billion)
  • FIG 17. Asia pacific Myasthenia Gravis Treatment Market 2018 & 2027 (USD Billion)
  • FIG 18. Latin America Myasthenia Gravis Treatment Market 2018 & 2027 (USD Billion)
  • FIG 19. Global Myasthenia Gravis Treatment Market, company market share analysis (2020)
目次

Global Myasthenia Gravis Market is valued approximately USD 1 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.2% over the forecast period 2021-2027. Myasthenia gravis is a chronic autoimmune and neuromuscular disease that leads weakness in the skeletal muscles. The disease worsens when muscles are active and improves after rest. These affected muscles are responsible for breathing and moving arms, legs and other parts of the body.

Th growing adoption of immunotherapies used to relive the symptoms and problems associated with myasthenia gravis along with the regular approval of hopeful drugs and treatments of this disease are propelling the market of Myasthenia Gravis. The increasing awareness of rare diseases among people, coupled with the growth of biosimilars and biologics industry, are driving the Myasthenia Gravis market. There are no know causes of Myasthenia Gravis and it can target anyone. National Organization for Rare Diseases reports that autoimmune myasthenia gravis has a prevalence of approximately 14-40 per 100,000 individuals in the United States. It also states that estimated 10 percent of patients affected by this disease may develop potentially life-threatening complications due to severe involvement of muscles, including those used during breathing. Organization also observes autoimmune myasthenia gravis more often affects women than men. The lack of awareness and testing of this disease and mis-diagnosis of Myasthenia Gravis may act as a restraint for its growth. However, increasing efforts from government and private players to understand this disease through studies and research acts as an opportunity for Myasthenia Gravis Market in subsequent decade.

Key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World are analysed to provide a holistic picture of Myasthenia Gravis Market. Due to higher awareness for autoimmune diseases and their treatment as well as higher per capita income, North America has emerged as the significant region across the world in terms of market share. Whereas, Asia-Pacific is expected to exhibit highest growth rate for the forecast period 2021-2027 owing to the growing diagnosis of the disease and better healthcare infrastructure. Rising disposable income and governmental push for the study of rare diseases will also boost growth in this region.

Major market player included in this report are:

Alexion Pharmaceutical Inc.

Grifols SA

Avadel Pharmaceuticals, Plc.

Novartis

Pfizer, Inc.

AbbVie Inc.

F.Hoffmann-La Roche AG

GlaxoSmithKline Plc.

Bausch Health Companies Inc.

Shire plc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Treatment:

Medication Market

Surgery Market

Others Market

By End-Use:

Hospitals Market

Clinics Market

Others Market

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2018, 2019

Base year - 2020

Forecast period - 2021 to 2027

Target Audience of the Global Myasthenia Gravis Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
    • 1.2.1. Myasthenia Gravis Treatment Market, by Treatment, 2019-2027 (USD Billion)
    • 1.2.2. Myasthenia Gravis Treatment Market, by End-Use, 2019-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Myasthenia Gravis Treatment Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Myasthenia Gravis Treatment Market Dynamics

  • 3.1. Myasthenia Gravis Treatment Market Impact Analysis (2019-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing awareness for the autoimmune diseases
      • 3.1.1.2. Growth of biologics and biosimilars industry
    • 3.1.2. Market Challenges
      • 3.1.2.1. Lack of awareness for Myasthenia Gravis disease
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Growing research in causes and treatment of Myasthenia Gravis

Chapter 4. Global Myasthenia Gravis Treatment Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Myasthenia Gravis Treatment Market, by Treatment

  • 5.1. Market Snapshot
  • 5.2. Global Myasthenia Gravis Treatment Market by Treatment, Performance - Potential Analysis
  • 5.3. Global Myasthenia Gravis Treatment Market Estimates & Forecasts by Treatment 2018-2027 (USD Billion)
  • 5.4. Myasthenia Gravis Treatment Market, Sub Segment Analysis
    • 5.4.1. Medication Market
    • 5.4.2. Surgery Market
    • 5.4.3. Others Market

Chapter 6. Global Myasthenia Gravis Treatment Market, by End-Use

  • 6.1. Market Snapshot
  • 6.2. Global Myasthenia Gravis Treatment Market by End-Use, Performance - Potential Analysis
  • 6.3. Global Myasthenia Gravis Treatment Market Estimates & Forecasts by End-Use 2018-2027 (USD Billion)
  • 6.4. Myasthenia Gravis Treatment Market, Sub Segment Analysis
    • 6.4.1. Hospitals Market
    • 6.4.2. Clinics Market
    • 6.4.3. Others Market

Chapter 7. Global Myasthenia Gravis Treatment Market, Regional Analysis

  • 7.1. Myasthenia Gravis Treatment Market, Regional Market Snapshot
  • 7.2. North America Myasthenia Gravis Treatment Market
    • 7.2.1. U.S. Myasthenia Gravis Treatment Market
      • 7.2.1.1. Treatment breakdown estimates & forecasts, 2018-2027
      • 7.2.1.2. End-Use breakdown estimates & forecasts, 2018-2027
    • 7.2.2. Canada Myasthenia Gravis Treatment Market
  • 7.3. Europe Myasthenia Gravis Treatment Market Snapshot
    • 7.3.1. U.K. Myasthenia Gravis Treatment Market
    • 7.3.2. Germany Myasthenia Gravis Treatment Market
    • 7.3.3. France Myasthenia Gravis Treatment Market
    • 7.3.4. Spain Myasthenia Gravis Treatment Market
    • 7.3.5. Italy Myasthenia Gravis Treatment Market
    • 7.3.6. Rest of Europe Myasthenia Gravis Treatment Market
  • 7.4. Asia-Pacific Myasthenia Gravis Treatment Market Snapshot
    • 7.4.1. China Myasthenia Gravis Treatment Market
    • 7.4.2. India Myasthenia Gravis Treatment Market
    • 7.4.3. Japan Myasthenia Gravis Treatment Market
    • 7.4.4. Australia Myasthenia Gravis Treatment Market
    • 7.4.5. South Korea Myasthenia Gravis Treatment Market
    • 7.4.6. Rest of Asia Pacific Myasthenia Gravis Treatment Market
  • 7.5. Latin America Myasthenia Gravis Treatment Market Snapshot
    • 7.5.1. Brazil Myasthenia Gravis Treatment Market
    • 7.5.2. Mexico Myasthenia Gravis Treatment Market
  • 7.6. Rest of The World Myasthenia Gravis Treatment Market

Chapter 8. Competitive Intelligence

  • 8.1. Top Market Strategies
  • 8.2. Company Profiles
  • 8.3. Alexion Pharmaceutical Inc.
      • 8.3.1.1. Key Information
      • 8.3.1.2. Overview
      • 8.3.1.3. Financial (Subject to Data Availability)
      • 8.3.1.4. Product Summary
      • 8.3.1.5. Recent Developments
    • 8.3.2. Grifols SA
    • 8.3.3. Avadel Pharmaceuticals, Plc.
    • 8.3.4. Novartis
    • 8.3.5. Pfizer, Inc.
    • 8.3.6. AbbVie Inc.
    • 8.3.7. F.Hoffmann-La Roche AG
    • 8.3.8. GlaxoSmithKline Plc.
    • 8.3.9. Bausch Health Companies Inc.
    • 8.3.10. Shire plc

Chapter 9. Research Process

  • 9.1. Research Process
    • 9.1.1. Data Mining
    • 9.1.2. Analysis
    • 9.1.3. Market Estimation
    • 9.1.4. Validation
    • 9.1.5. Publishing
  • 9.2. Research Attributes
  • 9.3. Research Assumption